27,671 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Kimelman & Baird LLC

Kimelman & Baird LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, Holdings Channel.com reports. The firm acquired 27,671 shares of the biopharmaceutical company’s stock, valued at approximately $17,254,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $3,183,000. Gabelli Funds LLC increased its stake in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after buying an additional 55 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,400 shares of company stock worth $1,090,030. Insiders own 6.97% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. Citigroup lifted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Leerink Partners raised their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Fifteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $800.36.

Regeneron Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:REGN opened at $794.19 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $717.52 and a two-hundred day moving average of $718.38. The stock has a market cap of $81.77 billion, a P/E ratio of 19.63, a PEG ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the firm earned $12.81 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.